Gaceta Médica, leading newspaper in health information, interviews Dra. Isabel Portero, CEO & Founder of BIOHOPE
"Closer to the personalization of renal transplant treatment. First study to evaluate the functionality of the immunobiogram to predict the immunosuppressive response." > Read More
Interview with Isabel Portero, Founder and Director of Biohope
Isabel talks about the way she has professionally evolved, the achievements she has made and the promising future of Biohope, a highly qualified innovative Clinical stage biotech Company, thanks to the enthusiasm, ability to work [...]
Different media publish the new of the success of the immunobiogram
Following the presentation of Biohope at the Congress of the International Society of Transplantation held in Madrid, the media have published different articles on the results of the clinical study that demonstrate the usefulness of [...]
First Patient in: TRANSBIO CLINICAL STUDY starts the recruitment
The TRANSBIO clinical study has started with inclusion of the first patient in the Hospital Puerta de Hierro (Madrid, Spain) on the 12th of June 2018, with Dr. José María Portoles as Principal Investigator. The University Hospital Puerta [...]
Biohope in Boston
Biohope is holding these days meetings in Boston with investors and companies for future collaborations in the development of the Inmunobiogram®, cutting-edge technology in the treatment of chronic inflammatory diseases that will allow the personalization of [...]
Biohope in Forbes List
Dra. Isabel Portero, Biohope´s CEO, has been included in the list of “100 Most Creative People in Business” published by Forbes. […]